BW1003C87 | 130801-42-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: BW1003C87
• 英文别名: 5-(2,3,5-trichlorophenyl)-2,4-diaminopyrimidine；2,4-diamino-5-(2,3,5-trichlorophenyl)pyrimidine；5-(2,3,5-Trichlorophenyl)pyrimidine-2,4-diamine
• CAS: 130801-42-2
• 化学式: C₁₀H₇Cl₃N₄
• 分子量: 289.551
• InChiKey: WKJFILILEWPMQF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  77.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS<br/>[FR] BLOQUEUR DE CANAUX SODIQUES TRIAZOÏQUES ET DIAZOÏQUES CYCLIQUES
  申请人：UNIV GREENWICH

  公开号：WO2009090431A1

  公开（公告）日：2009-07-23

  Compounds of general structure in which X and Y are each N or C with at least one of X and Y being N; Z is a single bond or an optionally substituted linking group R1 is hydrogen or a substituent group; R2 is amino or a substituent group; N* is amino when RI is hydrogen or =NH when R1 is a substituent group; or N* is a group NRaRb where Ra and Rb are independently H or an alkyl group; or N* is an optionally substituted piperazinyl ring; and A is an optionally substituted heterocyclic or carbocyclic ring system which may be linked to the triazo/diazo ring through R2 to form a fused multicyclic ring; are indicated as suitable for treatment of disorders in mammals that are susceptible to sodium channel blockers and antifolates, and particularly disorders such epilepsy, multiple sclerosis, glaucoma and uevitis, cerebral traumas and cerebral ischaemias, stroke, head injury, spinal cord injury, surgical trauma, neurodegenerative disorders, motorneurone disease, Alzheimer's disease, Parkinson's disease, chronic inflammatory pain, neuropathic pain, migraine, bipolar disorder, mood, anxiety and cognitive disorders, schizophrenia and trigeminal autonomic cephalalgias; for treatment of mammalian cancers; and for treatment of malaria.

  通用结构化合物，其中X和Y分别为N或C，至少X和Y中的一个为N；Z是单键或可选择性取代的连接基团；R1是氢或取代基团；R2是氨基或取代基团；N*是氨基，当R1为氢或=NH时，当R1为取代基团时；或N*是一个NRaRb基团，其中Ra和Rb分别为H或烷基基团；或N*是一个可选择性取代的哌嗪环；A是一个可选择性取代的杂环或碳环系统，可以通过R2与三唑/重氮环连接形成融合的多环环；适用于治疗对钠通道阻滞剂和抗叶酸类药物敏感的哺乳动物的疾病，特别是癫痫、多发性硬化、青光眼和葡萄膜炎、脑外伤和脑缺血、中风、头部损伤、脊髓损伤、手术创伤、神经退行性疾病、运动神经元疾病、阿尔茨海默病、帕金森病、慢性炎症性疼痛、神经病性疼痛、偏头痛、双相情感障碍、情绪、焦虑和认知障碍、精神分裂症和三叉神经自主性头痛；用于治疗哺乳动物癌症；以及用于治疗疟疾。
• CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS
  申请人：University of Greenwich

  公开号：US20140155403A1

  公开（公告）日：2014-06-05

  A method of treating a disorder. The method includes administering to a subject in need thereof a compound of formula (I): Each of A, N*, X, Y, Z, R1, and R2 is defined herein. Also disclosed are compounds of the formula and a pharmaceutical composition containing such a compound.

  一种治疗疾病的方法。该方法包括向需要治疗的受试者施用式（I）的化合物：其中A、N*、X、Y、Z、R1和R2均在此定义。还公开了该式的化合物和包含该化合物的制药组合物。
• Pharmacologically active CNS compounds
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0372934A2

  公开（公告）日：1990-06-13

  A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.

  本研究公开了一类取代苯基嘧啶化合物，它们是兴奋性氨基酸谷氨酸的强效抑制剂。此类化合物可用于治疗或预防一系列中枢神经系统疾病，包括脑缺血损伤和癫痫。
• Pharmacologically active CNS compound
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0459819A2

  公开（公告）日：1991-12-04

  The invention provides a series of compounds of formula (I) and salts thereof, wherein for example, R¹ and R², which may be the same or different each represent -NR¹³R¹⁴ where R¹³ and R¹⁴ may each independently represent hydrogen or alkyl or, taken together with the nitrogen atom to which they are attached form a heterocyclic ring, optionally substituted by one or more alkyl or arylalkyl groups and optionally containing a further heteroatom; R³ is hydrogen, haloalkyl, alkoxymethyl or alkyl; R⁴ is hydrogen, nitro or halo; R⁵ is hydrogen or halo; R⁶ is hydrogen, halo, nitro, amino, alkylamino or dialkylamino; R⁷ is hydrogen or halo; R⁸ is hydrogen or halo; The compounds may be used for the treatment or prophylaxis of a neurodegenerative or other neurological disorder of the CNS, the aetiology or which includes excessive release of the neurotransmitter glutamate.

  本发明提供了一系列式 (I) 的化合物 及其盐类，其中例如 R¹和R²可以相同或不同，各自代表-NR¹³R¹⁴，其中R¹³和R¹⁴可以各自独立地代表氢或烷基，或与它们所连接的氮原子一起形成杂环，任选被一个或多个烷基或芳烷基取代，并任选含有另一个杂原子； R³ 是氢、卤代烷基、烷氧基甲基或烷基； R⁴ 是氢、硝基或卤代； R⁵ 是氢或卤素； R⁶ 是氢、卤素、硝基、氨基、烷基氨基或二烷基氨基； R⁷ 是氢或卤素； R⁸ 是氢或卤素； 这些化合物可用于治疗或预防中枢神经系统的神经退行性疾病或其他神经疾病，其病因或包括神经递质谷氨酸的过度释放。
• Pharmacologically active CNS pyridmidin compounds
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0679645A1

  公开（公告）日：1995-11-02

  A series of phenylpyrimidines and acid addition salts thereof are inhibitors of extracellular glutamate release. They have negligible effect against the enzyme dihydrofolate reductase. They are useful in the treatment or prophylaxis in a mammal of a neurodegenerative or other neurological disorder of the central nervous system, the aetiology of which includes excessive release of neurotransmitter glutamate.

  一系列苯基嘧啶及其酸加成盐是细胞外谷氨酸释放的抑制剂。 它们对二氢叶酸还原酶的作用微乎其微。 它们可用于治疗或预防哺乳动物中枢神经系统的神经退行性疾病或其他神经疾病，这些疾病的病因包括神经递质谷氨酸的过度释放。